The Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling
pathway was discovered more than a quarter-century ago. As a fulcrum of many vital cellular …

This document updates the recommendations on the management of Philadelphia
chromosome-negative myeloproliferative neoplasms (Ph-neg MPNs) published in 2011 by …

The classic Philadelphia chromosome–negative myeloproliferative neoplasms (MPN)
consist of myelofibrosis, polycythemia vera, and essential thrombocythemia and are a …

Introduction: Protein kinases are involved in various cellular functions. About 2% of the
human genome encodes for protein kinases. Dysregulation of protein kinases is implicated …

Myeloid neoplasms, including acute myeloid leukemia (AML), myeloproliferative neoplasms
(MPNs), and myelodysplastic syndromes (MDS), feature clonal dominance and remodeling …

Prior studies have reported high response rates with recombinant interferon-α (rIFN-α)
therapy in patients with essential thrombocythemia (ET) and polycythemia vera (PV). To …

Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to
Hydroxycarbamide in a Randomized Trial - PMC Back to Top Skip to main content NIH NLM …

Myeloproliferative neoplasms are associated with increased risk for thrombotic
complications. These conditions most commonly involve somatic mutations in genes that …

Ruxolitinib exerts immunosuppressive activity that may increase the risk of infectious
complications. We performed a systematic review of the literature with the aim of estimating …

Disease overview Polycythemia vera (PV) and essential thrombocythemia (ET) are
myeloproliferative neoplasms (MPN) respectively characterized by clonal erythrocytosis and …